Jean Yves brings over 35 years experience in Biotechnology company leadership and therapeutic drug development. He has worked for several biotech and big Pharma companies from bench to managerial positions (Schering-Plough, GSK, Pierre Fabre, Transgene). Jean Yves technical experience has been in antibodies, antibody-drug-conjugates (ADC), cell therapy, gene editing, gene therapy, induced-pluripotent-stem-cells (iPSC), new-chemical-entity (NCE), oncolytics, peptides, and therapeutic vaccines. Additionally, Jean Yves has been Co-founder, CEO and Chairman on multiple biotech startups. When not finding novel drug therapies, Jean Yves likes to enjoy fine food and long walks in the mountains.